10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors

10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors

Heparin-induced thrombocytopenia (HIT) is an immune-mediated, life-threatening adverse drug reaction characterized by a paradoxical prothrombotic state occurring in the setting of falling platelet counts. Unlike non-immune drug-induced thrombocytopenias where mucosal bleeding and petechiae predominate, the primary clinical danger of HIT is catastrophic arterial and venous thrombosis—a syndrome termed Heparin-Induced Thrombocytopenia and Thrombosis (HITT). Untreated, HIT carries a 30-day thrombotic risk of 30% to 50% and a mortality rate of 10% to 20%. Rapid recognition via clinical scoring, prompt laboratory testing, immediate cessation of all heparin exposures, and urgent initiation of non-heparin anticoagulation are paramount.

---

Pathophysiology: Immune-Mediated Thrombosis

It is clinically vital to distinguish between benign Type I HIT and life-threatening Type II HIT:

• Type I HIT: A benign, non-immune phenomenon occurring within the first 1 to 2 days of heparin exposure due to direct, transient platelet aggregation. Platelet counts rarely drop below $100,000/\text{mcL}$ and normalize spontaneously without discontinuing heparin.
• Type II HIT: An immune-mediated reaction involving IgG autoantibodies that typically manifests 5 to 10 days following heparin exposure.

Loading diagram...

Molecular Cascade of Type II HIT

1. PF4-Heparin Complex Formation: Platelet Factor 4 (PF4) is a positively charged chemokine stored within platelet alpha-granules. When heparin (a negatively charged polyanion) is introduced, it binds PF4, inducing a conformational change that exposes cryptic immunogenic neoepitopes.
2. IgG Antibody Generation: The patient produces polyclonal IgG antibodies specific to these PF4-heparin complexes.
3. Fc-gamma-RIIa Receptor Cross-Linking: The circulating IgG-PF4-heparin immune complexes bind to Fc-gamma-RIIa (CD32) receptors on platelet surfaces. Cross-linking of multiple Fc receptors stimulates intense, explosive platelet activation.
4. Thrombin Generation & Endothelial Damage: Activated platelets shed procoagulant microparticles that dramatically accelerate systemic thrombin generation. Concurrently, PF4 binds to heparan sulfate on vascular endothelial cells, allowing antibody binding that injures the endothelium and triggers tissue factor release.
5. Platelet Consumption: Platelets are rapidly consumed in microvascular thrombi and cleared by the reticuloendothelial system, causing thrombocytopenia alongside widespread thrombosis.

---

Pretest Probability Assessment: The 4Ts Clinical Scoring System

The 4Ts Score is the gold-standard, validated clinical pretest probability instrument required prior to ordering laboratory testing:

Risk Stratification & Clinical Directives

• Low Probability (Score 0 to 3): True probability of HIT is $<2\%$. Negative predictive value is $>98\%$. Do NOT order laboratory assays; continue heparin if indicated and investigate alternative etiologies.
• Intermediate Probability (Score 4 to 5): Probability of HIT is approximately $10\%\text{ to }15\%$. Immediately stop all heparin products and initiate an alternative non-heparin parenteral anticoagulant while awaiting diagnostic laboratory results.
• High Probability (Score 6 to 8): Probability of HIT is $40\%\text{ to }65\%$. Immediately discontinue all heparin, initiate therapeutic-dose non-heparin anticoagulation, and order bilateral lower extremity Doppler ultrasounds to screen for subclinical deep vein thrombosis.

---

Diagnostic Laboratory Workup: Immunoassays vs. Functional Assays

Definitive diagnosis requires a two-step laboratory paradigm pairing an immunoassay with a functional confirmatory test:

1. PF4-Heparin Enzyme-Linked Immunosorbent Assay (ELISA)

• Technique: Detects circulating antibodies binding to immobilized PF4-heparin complexes.
• Characteristics: High sensitivity ($>95\%\text{ to }98\%$) with excellent negative predictive value, but low-to-moderate specificity ($50\%\text{ to }70\%$). Many critically ill and post-cardiac surgery patients develop non-pathogenic antibodies that do not activate platelets.
• Optical Density (OD) Thresholds:
  • $\text{OD} < 0.40$: Negative (rules out HIT with $>99\%$ certainty).
  • $\text{OD } 0.40\text{ to }0.99$: Weakly positive (frequently false-positive; clinical probability ~5–10%).
  • $\text{OD } 1.00\text{ to }1.99$: Moderately positive (clinical probability ~50%).
  • $\text{OD } \ge 2.00$: Strongly positive (clinical probability $>90\%$).

2. Serotonin Release Assay (SRA) — Gold Standard

• Technique: Functional confirmatory assay measuring actual platelet activation.
• Protocol: Donor platelets are radiolabeled with carbon-14 ($^{14}\text{C}$)-serotonin and incubated with patient serum in the presence of therapeutic ($0.1\text{ to }0.5\text{ IU/mL}$) and supratherapeutic ($100\text{ IU/mL}$) heparin concentrations.
• Diagnostic Criteria: A positive result requires $\ge 20\%$ serotonin release at therapeutic heparin levels, which is completely suppressed ($<20\%$) at supratherapeutic (100 IU/mL) heparin (because excess heparin dismantles the multimolecular PF4-heparin lattice).

---

Acute Management Protocols & Critical Pitfalls

                             CRITICAL PITFALLS IN ACUTE HIT
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. NEVER TRANSFUSE PLATELETS: Platelets fuel Fc-receptor activation and     │
  │    trigger acute arterial thrombosis. Transfuse only for life-threatening   │
  │    active bleeding.                                                         │
  │ 2. NEVER START WARFARIN MONOTHERAPY: Depletes Protein C before Factor II,   │
  │    precipitating microvascular thrombosis and venous limb gangrene.         │
  │ 3. ELIMINATE ALL HEPARIN SOURCES: Flushes, coated catheters, CRRT circuits. │
  └─────────────────────────────────────────────────────────────────────────────┘

Immediate Resuscitation Directives

1. Discontinue All Heparin Immediately: Stop all unfractionated heparin infusions and LMWH injections. Replace heparin flushes on all arterial lines, central lines, and peripheral IVs with 0.9% sodium chloride. Remove or replace heparin-coated vascular catheters.
2. Do Not Transfuse Platelets: Platelet transfusions add substrate to the prothrombotic fire, directly precipitating acute stroke, limb ischemia, and myocardial infarction. Thrombocytopenia in HIT is rarely associated with bleeding.
3. Do Not Administer Warfarin in the Acute Phase: Initiating warfarin monotherapy or loading doses during acute HIT causes rapid depletion of Protein C (half-life 6 to 8 hours) while prothrombin (Factor II, half-life 60 to 72 hours) remains intact. This creates an uninhibited procoagulant state that triggers microvascular thrombosis, skin necrosis, and venous limb gangrene.

---

Non-Heparin Direct Thrombin Inhibitors (DTIs) & Fondaparinux

Once heparin is halted, therapeutic parenteral anticoagulation must be initiated immediately for intermediate or high pretest probability cases.

Argatroban

Argatroban is a small-molecule synthetic univalent direct thrombin inhibitor derived from L-arginine that selectively and reversibly binds to the catalytic active site of free and clot-bound thrombin.

• Metabolism & Clearance: 100% hepatic metabolism (hydroxylation and aromatization) and biliary excretion. Elimination half-life is 40 to 50 minutes. No renal dosage adjustment is required.
• Dosing Regimens:
  • Normal Hepatic Function: Initiate continuous IV infusion at 2.0 mcg/kg/min (no IV bolus).
  • Hepatic Impairment / Critical Illness: In patients with moderate-to-severe hepatic impairment (Child-Pugh Class B or C, total bilirubin $>1.5\text{ mg/dL}$), ICU admission, multiorgan failure, or status-post cardiac surgery, clearance is dramatically reduced. Initiate at 0.5 mcg/kg/min (or $0.2\text{ mcg/kg/min}$ in severe hepatic failure).
• Monitoring: Titrate to an activated partial thromboplastin time (aPTT) of 1.5 to 3.0 times baseline (typically 60 to 90 seconds, not to exceed 100 seconds). Measure aPTT 2 hours after initiation or rate titration.
• Warfarin Transition Protocol:
  • Argatroban directly prolongs the prothrombin time and elevates the INR (alone, it elevates INR to 1.5–3.5).
  • Prerequisites: Platelets must fully recover to $\ge 150,000/\text{mcL}$ before initiating warfarin.
  • Co-administration: Initiate warfarin at expected maintenance doses ($\le 5\text{ mg}$; never load). Co-administer argatroban and warfarin for a minimum of 5 days AND until the combined INR exceeds 4.0 (on argatroban doses $\le 2\text{ mcg/kg/min}$).
  • Discontinuation: Once combined INR $>4.0$, temporarily pause argatroban for 4 to 6 hours and recheck INR on warfarin monotherapy. If the monotherapy INR is therapeutic (2.0 to 3.0), discontinue argatroban; if subtherapeutic, resume argatroban and re-evaluate. Alternatively, use a Chromogenic Factor X assay (unaffected by argatroban; goal Factor X activity $<40\text{ to }45\%$).

Bivalirudin

Bivalirudin is a synthetic 20-amino acid bivalent direct thrombin inhibitor that binds simultaneously to thrombin's active catalytic site and exosite 1.

• Metabolism & Clearance: 80% organ-independent enzymatic/proteolytic cleavage by circulating proteases; 20% renal elimination. Elimination half-life is 25 minutes in normal renal function (prolonged to 60 to 120 minutes in ESRD).
• Dosing: Continuous IV infusion at 0.15 to 0.20 mg/kg/h for HIT; titrate to aPTT 1.5 to 2.5 times baseline. In patients undergoing urgent percutaneous coronary intervention (PCI), administer an IV bolus of 0.75 mg/kg followed by 1.75 mg/kg/h infusion.
• Clinical Role: Preferred agent in patients with severe hepatic dysfunction, combined hepatorenal failure, or patients requiring urgent cardiac catheterization. Produces minimal INR elevation.

Fondaparinux

Fondaparinux is a synthetic pentasaccharide that selectively binds antithrombin, accelerating Factor Xa inhibition. It does not cross-react with PF4 antibodies.

• Clearance: 100% renal elimination (half-life 17 to 21 hours). Strictly contraindicated in severe renal impairment ($\text{CrCl} < 30\text{ mL/min}$).
• Direct Oral Anticoagulants: The 2018 ASH HIT guideline lists DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) as acceptable options for clinically stable patients with acute HIT who are not at high bleeding risk. They avoid the INR overlap problems of warfarin, though data are smaller than for argatroban.
• Clinical Role: Supported by current guidelines as an off-label subcutaneous option ($5\text{ mg}$ if $<50\text{ kg}$, $7.5\text{ mg}$ if $50\text{--}100\text{ kg}$, $10\text{ mg}$ if $>100\text{ kg}$ once daily) in hemodynamically stable, non-critically ill patients with preserved renal function.

---

Direct Thrombin Inhibitor Comparison Matrix